REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
Portfolio Pulse from
Kahn Swick & Foti, LLC is investigating the proposed sale of Revance Therapeutics, Inc. to Crown Laboratories, Inc. The investigation focuses on the adequacy of the $3.10 per share offer and the process leading to the sale.
December 17, 2024 | 7:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Revance Therapeutics is under investigation by Kahn Swick & Foti, LLC regarding its proposed sale to Crown Laboratories. The focus is on the adequacy of the $3.10 per share offer.
The investigation by Kahn Swick & Foti, LLC into the adequacy of the sale price could lead to uncertainty and potential delays in the transaction, negatively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100